Related Experiment Video

Updated: May 24, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Co-development of a companion diagnostic for targeted cancer therapy

Suzanne Cheng1, Walter H Koch, Lin Wu

  • 1Roche Molecular Systems, Inc., 4300 Hacienda Dr, Pleasanton, CA 94588, USA. suzanne.cheng@roche.com

New Biotechnology
|March 7, 2012
PubMed

Insights

Co-developing vemurafenib, a BRAF kinase inhibitor, with its companion diagnostic test improved metastatic melanoma treatment success. This personalized medicine approach significantly shortened development timelines for oncology drugs.

Area of Science:

  • Oncology
  • Pharmacogenomics
  • Molecular Diagnostics

Background:

  • Oncology drug development has a low success rate (5-10%) and high costs.
  • Metastatic melanoma presents significant survival challenges.
  • The BRAF kinase gene mutation is a key target in melanoma.

Purpose of the Study:

  • To describe the co-development of vemurafenib and its companion diagnostic test.
  • To highlight factors contributing to successful personalized medicine development.
  • To demonstrate accelerated drug and diagnostic development for metastatic melanoma.

Main Methods:

  • Co-development of vemurafenib (BRAF kinase inhibitor) and the cobas® 4800 BRAF V600 Mutation Test.
  • Early identification and validation of the BRAF V600E biomarker.
  • Close collaboration between pharmaceutical and diagnostic development teams.

Main Results:

  • Successful co-development of a targeted therapy and its companion diagnostic.
  • Vemurafenib and the BRAF V600 Mutation Test represent the first personalized medicine for metastatic melanoma.
  • Development time was significantly reduced, achieving approval in under five years.

Conclusions:

  • Integrated, parallel development of targeted therapies and companion diagnostics enhances success rates.
  • Early biomarker identification and collaborative development are crucial for personalized medicine.
  • This model offers a pathway to accelerate the delivery of effective cancer treatments.

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...